NU 2022-129 INVENTORS
SHORT DESCRIPTION
This invention offers a tissue expander that integrates drug delivery for breast reconstruction. It provides gradual inflation while releasing therapeutic agents to support improved healing. BACKGROUND
Implant-based breast reconstruction is the most common method following mastectomy, accounting for over 75% of procedures in the United States. Surgeons face challenges with the two-stage process and high costs related to multiple surgeries. Current devices do not combine tissue expansion with localized drug delivery, leaving an unmet clinical need for improved patient outcomes. ABSTRACT
The invention introduces a novel tissue expander that incorporates drug delivery functionality. It is designed to gradually inflate and form a breast pocket while simultaneously releasing therapeutic agents. Preliminary testing in controlled laboratory settings has shown that it meets target performance metrics for both tissue expansion and localized therapy, promising enhanced treatment outcomes for cancer patients undergoing reconstructive surgery. MARKET OPPORTUNITY
The global breast reconstruction market was valued at over $615 million in 2023 and is projected to expand at a CAGR of 7.9% through 2030 (Source: Grand View Research, 2024) DEVELOPMENT STAGE
TRL-4 - Prototype Validated in Lab: Key functions, including controlled inflation and drug release, have been successfully demonstrated in a laboratory environment. APPLICATIONS
ADVANTAGES
IP STATUS
US Patent Pending